{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:25:22Z","timestamp":1783164322168,"version":"3.54.6"},"reference-count":82,"publisher":"Georg Thieme Verlag KG","issue":"10","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Asbestverursachte maligne Mesotheliome geh\u00f6ren in Deutschland mit etwa 1000 j\u00e4hrlichen Neuerkrankungen zu den h\u00e4ufigen arbeitsbedingten Krebserkrankungen. Die Prognose ist oftmals schlecht, da die Erkrankung lange symptomlos bleibt und deshalb meist erst als Zufallsbefund in bereits fortgeschrittenen Stadien diagnostiziert wird.<\/jats:p><jats:p>Die deutsche gesetzliche Unfallversicherung (DGUV) hat in den letzten Jahren erhebliche Anstrengungen unternommen, eine Vorverlagerung des Diagnosezeitpunkts zu erreichen, um die Erkrankung m\u00f6glichst in Fr\u00fchstadien zu detektieren. Die aus diesen Bestrebungen resultierenden neuen medizinisch-wissenschaftlichen Erkenntnisse zeigen, dass die Kombination der Biomarker Calretinin und Mesothelin in einer Hochrisikogruppe die Vorverlegung der Diagnose um bis zu 12 Monaten erm\u00f6glicht.<\/jats:p><jats:p>Die Diagnose eines Mesothelioms im Fr\u00fchstadium wird idealerweise von der individuell bestm\u00f6glichen Therapie gefolgt. Die Standardtherapie basiert auf operativer Entfernung des Tumors und Chemotherapie, erg\u00e4nzt um Strahlentherapie und Psychoonkologie. In den letzten Jahren wurden einige neue Therapieans\u00e4tze entwickelt. Die \u00dcbersicht stellt den aktuellen Stand der Therapie des Mesothelioms, basierend auf den internationalen Leitlinien und neuen Studien, dar.<\/jats:p>","DOI":"10.1055\/a-1404-1562","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T22:47:47Z","timestamp":1620168467000},"page":"776-794","source":"Crossref","is-referenced-by-count":6,"title":["Die aktuelle Therapie des asbestassoziierten malignen Pleuramesothelioms \u2013 Ein Experten-Konsensuspapier"],"prefix":"10.1055","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-991X","authenticated-orcid":false,"given":"C.","family":"Aigner","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Thoraxchirurgie und thorakale Endoskopie, Universit\u00e4tsmedizin Essen \u2212 Ruhrlandklinik"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Br\u00fcning","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pr\u00e4vention und Arbeitsmedizin der Deutschen Gesetzlichen Unfallversicherung (DGUV) \u2013 Institut der Ruhr-Universit\u00e4t Bochum"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-9931","authenticated-orcid":false,"given":"W. E. E.","family":"Eberhardt","sequence":"additional","affiliation":[{"name":"Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Ruhrlandklinik, Universit\u00e4tsmedizin Essen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7443-9890","authenticated-orcid":false,"given":"M.","family":"H\u00e4rter","sequence":"additional","affiliation":[{"name":"Institut und Poliklinik f\u00fcr Medizinische Psychologie und Institut f\u00fcr Psychotherapie (IfP), Universit\u00e4tsklinikum Hamburg-Eppendorf"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-5924","authenticated-orcid":false,"given":"H.-P.","family":"Kaelberlah","sequence":"additional","affiliation":[{"name":"Strahlentherapie, MVZ an der Lungenklinik Hemer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5395-9010","authenticated-orcid":false,"given":"M.","family":"Metzenmacher","sequence":"additional","affiliation":[{"name":"Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Ruhrlandklinik, Universit\u00e4tsmedizin Essen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-0369","authenticated-orcid":false,"given":"R.","family":"Shah","sequence":"additional","affiliation":[{"name":"Internistische Onkologie der Thoraxtumoren, Thoraxklinik \u2212 Universit\u00e4tsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-1398","authenticated-orcid":false,"given":"C.","family":"Taube","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Pneumologie, Universit\u00e4tsmedizin Essen \u2013 Ruhrlandklinik"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-055X","authenticated-orcid":false,"given":"M.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Internistische Onkologie der Thoraxtumoren, Thoraxklinik \u2212 Universit\u00e4tsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"ref1","first-page":"67","article-title":"Merkblatt zur BK-Nr. 4105. Durch Asbest verursachtes Mesotheliom des Rippenfells, des Bauchfells oder des Perikards","volume":"1","author":"Bundesministerium f\u00fcr Arbeit","year":"1994","journal-title":"Bundesarbeitsbl"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1038\/s41598-018-32315-3","article-title":"Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin \u2013 a case-control comparison nested into a prospective cohort of asbestos-exposed workers","volume":"8","author":"G Johnen","year":"2018","journal-title":"Sci Rep"},{"issue":"S 05","key":"ref5","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"P Baas","year":"2015","journal-title":"Annals of Oncology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"H L Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e000266","DOI":"10.1136\/bmjresp-2017-000266","article-title":"BTS guideline for the investigation and management of malignant pleural mesothelioma","volume":"5","author":"I Woolhouse","year":"2018","journal-title":"Brit Med J Open Resp Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"A Scherpereel","year":"2010","journal-title":"Euro Respir J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"A Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the histologic classification of pleural mesothelioma: Towards a more multidisciplinary approach","volume":"15","author":"A G Nicholson","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma","volume":"7","author":"L Berzenji","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jtcvs.2013.01.039","article-title":"The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting summary of the International Mesothelioma Interest Group Congress, September 11\u201314, 2012, Boston, Mass","volume":"145","author":"V Rusch","year":"2013","journal-title":"J Thorac Cardiovas Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.21037\/atm.2017.03.88","article-title":"A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"5","author":"I Opitz","year":"2017","journal-title":"Ann Transl Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1601428","DOI":"10.1183\/13993003.01428-2016","article-title":"Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma","volume":"49","author":"M De Perrot","year":"2017","journal-title":"Eur Respir J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortictaion versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"E Taioli","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jtho.2017.02.026","article-title":"Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma","volume":"12","author":"F Shaikh","year":"2017","journal-title":"J Thorac Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.athoracsur.2016.08.071","article-title":"Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years","volume":"103","author":"J S Friedberg","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.21037\/atm.2017.04.05","article-title":"Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned","volume":"5","author":"D A Waller","year":"2017","journal-title":"Ann Transl Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.21037\/atm.2017.04.03","article-title":"Pleurectomy and decortication","volume":"5","author":"T Vlahu","year":"2017","journal-title":"Ann Transl Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.athoracsur.2015.04.151","article-title":"Extended pleurectomy and decortication for malignant pleural mesothelioma is an effective and safe cytoreductive surgery in the elderly","volume":"100","author":"T Williams","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/JTO.0000000000000064","article-title":"Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients","volume":"9","author":"P Bovolato","year":"2014","journal-title":"J Thorac Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study","volume":"12","author":"T Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"R A Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00104-019-0989-y","article-title":"Hypertherme intrathorakale Chemotherapie in der Thoraxchirurgie","volume":"90","author":"H S Hofmann","year":"2019","journal-title":"Chirurg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.18632\/oncotarget.220625","article-title":"Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"8","author":"Z Y Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"N J Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"G L Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"B Castagneto","year":"2008","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"A Santoro","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1200\/JCO.2016.34.15_suppl.8554","article-title":"Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis","volume":"34","author":"S A Srour","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"N Katirtzoglou","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"P375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"P Baas","year":"2021","journal-title":"The Lancet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","article-title":"Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study","volume":"17","author":"M J Byrne","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"G V Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/JTO.0b013e31817c73ec","article-title":"Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program","volume":"3","author":"P Taylor","year":"2008","journal-title":"J Thorac Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"M F Muers","year":"2008","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized Phase III Study of Cisplatin with or without Raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"J P Meerbeck van","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"8157","DOI":"10.1200\/JCO.2019.37.15_suppl.8517","article-title":"Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance)","volume":"37","author":"A Z Dudek","year":"2019","journal-title":"J Clin Oncol"},{"issue":"S 05","key":"ref39","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"Switch maintenance gemcitabine after first line chemotherapy in patients with malignant mesothelioma: a multicenter open label phase II trial (NVALT19). Poster presented at: European Society for Medical Oncology. Annual Meeting; 27 September\u20131 October 2019, Barcelona, Spain","volume":"30","author":"J A Burgers","year":"2019","journal-title":"Ann Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"G Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"G L Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14712598.2019.1606209","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"A K Nowak","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"G M Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","article-title":"Second-line treatment for malignant pleural mesothelioma","volume":"36","author":"G L Ceresoli","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"C Manegold","year":"2005","journal-title":"Ann Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","article-title":"Phase II study of vinorelbine in patients with malignant pleural mesothelioma","volume":"18","author":"J P Steele","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.rmed.2018.06.026","article-title":"A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","volume":"141","author":"F Petrelli","year":"2018","journal-title":"Respir Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2020.38.15_suppl.9004","article-title":"Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study","volume":"38","author":"M Pagano","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14712598.2019.1606209","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"A K Nowak","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1378\/chest.121.6.1921","article-title":"Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study","volume":"121","author":"I Monnet","year":"2002","journal-title":"Chest"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.10.005","article-title":"A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol","author":"R Shah","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/JCO.2018.36.15_suppl.8503","article-title":"DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma \u2013 First results","volume":"36","author":"A K Nowak","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1200\/JCO.2020.38.15_suppl.9003","article-title":"PrE0505: A phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) \u2013 A PrECOG LLC study. ASCO Virtual Scientific Program: American Society of Clinical Oncology","volume":"38","author":"P M Forde","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"E W Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"R Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"s339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"OA08.03 Phase II trial of pembrolizumab (NCT02399371) in ireviously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"A Desai","year":"2018","journal-title":"J Thorac Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"M Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 block-ade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"J Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"v931","DOI":"10.1093\/annonc\/mdz394.091","article-title":"Multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"30","author":"S C-F A Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"M Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"A Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"L Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"M J Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"ref65","volume-title":"Therapiekonzepte Onkologie. 4. Aufl","author":"S Seeber","year":"2004"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1016\/S0167-8140(19)30920-X","article-title":"OC-0500 radical hemi-thoracic radiotherapy vs. palliative radiotherapy for malignant pleural mesothelioma","volume":"133","author":"E Minatel","year":"2019","journal-title":"Radiother Oncol"},{"key":"ref67","first-page":"254","article-title":"Erfahrungen \u00fcber die Vertr\u00e4glichkeitsgrenze f\u00fcr R\u00f6ntgenstrahlen und deren Nutzanwendung zur Verh\u00fctung von Sch\u00e4den","volume":"57","author":"H Holthusen","year":"1936","journal-title":"Strahlenther"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 Phase 1 Trial","volume":"18","author":"N Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"J G Edwards","year":"2000","journal-title":"Thorax"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"A O Clive","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.18.01678","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: An open-label, multicenter, phase III randomized trial","volume":"37","author":"N Bayman","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3978\/j.issn.2225-319X.2012.11.05","article-title":"Standardizing Surgical Treatment in Malignant Pleural Mesothelioma","volume":"1","author":"D Rice","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1067\/mtc.2001.116560","article-title":"A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"122","author":"V W Rusch","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"R A Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(16)00024-3","article-title":"Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?","volume":"17","author":"A Rimner","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"M Perrot","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ijrobp.2005.03.041","article-title":"Hemithoracic radiation therapy after pleurectomy\/decortication for malignant pleural mesothelioma","volume":"63","author":"V Gupta","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3978\/j.issn.2225-319X.2012.10.07","article-title":"Novel radiation therapy approaches in malignant pleural mesothelioma","volume":"1","author":"A Rimner","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"A Rimner","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1016\/S0167-8140(19)30920-X","article-title":"OC-0500 radical hemi-thoracic radiotherapy vs. palliative radiotherapy for malignant pleural mesothelioma","volume":"133","author":"E Minatel","year":"2019","journal-title":"Radiother Oncol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/(SICI)1099-1611(199803\/04)7:2<126::AID-PON291>3.0.CO;2-A","article-title":"Stress associated with asbestosis: the trauma of waiting for death","volume":"7","author":"Y Barak","year":"1998","journal-title":"Psychooncology"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/pon.3162","article-title":"\u201eIt\u02bcs all bad news\u201c: the first 3 months following a diagnosis of malignant pleural mesothelioma","volume":"22","author":"A Arber","year":"2013","journal-title":"Psychooncology"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1200\/JCO.2014.56.0086","article-title":"Four-week prevalence of mental disorders in patients with cancer across major tumor entities","volume":"32","author":"A Mehnert","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000446991","article-title":"Twelve-month and lifetime prevalence of mental disorders in cancer patients","volume":"85","author":"S Kuhnt","year":"2016","journal-title":"Psychother Psychosom"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1200\/JCO.2017.77.1097","article-title":"Managing cancer and living meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer","volume":"36","author":"G Rodin","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1404-1562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:06:47Z","timestamp":1637712407000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1404-1562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":82,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,18]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1404-1562","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"value":"0934-8387","type":"print"},{"value":"1438-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}